AU2017274094B2 - Compositions and methods for treating metabolic diseases - Google Patents

Compositions and methods for treating metabolic diseases Download PDF

Info

Publication number
AU2017274094B2
AU2017274094B2 AU2017274094A AU2017274094A AU2017274094B2 AU 2017274094 B2 AU2017274094 B2 AU 2017274094B2 AU 2017274094 A AU2017274094 A AU 2017274094A AU 2017274094 A AU2017274094 A AU 2017274094A AU 2017274094 B2 AU2017274094 B2 AU 2017274094B2
Authority
AU
Australia
Prior art keywords
polypeptide
cmyr
subject
serum
ntcp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017274094A
Other languages
English (en)
Other versions
AU2017274094A1 (en
Inventor
Hongli Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI HEP PHARMACEUTICAL Co Ltd
Original Assignee
SHANGHAI HEP PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI HEP PHARMACEUTICAL CO Ltd filed Critical SHANGHAI HEP PHARMACEUTICAL CO Ltd
Publication of AU2017274094A1 publication Critical patent/AU2017274094A1/en
Application granted granted Critical
Publication of AU2017274094B2 publication Critical patent/AU2017274094B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2017274094A 2016-05-30 2017-05-31 Compositions and methods for treating metabolic diseases Active AU2017274094B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610370442.4 2016-05-30
CN201610370442 2016-05-30
PCT/CN2017/086558 WO2017206898A1 (en) 2016-05-30 2017-05-31 Compositions and methods for treating metabolic diseases

Publications (2)

Publication Number Publication Date
AU2017274094A1 AU2017274094A1 (en) 2019-02-14
AU2017274094B2 true AU2017274094B2 (en) 2020-09-10

Family

ID=60479717

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017274094A Active AU2017274094B2 (en) 2016-05-30 2017-05-31 Compositions and methods for treating metabolic diseases

Country Status (10)

Country Link
US (2) US11633454B2 (enExample)
EP (1) EP3463422B1 (enExample)
JP (1) JP7684788B2 (enExample)
KR (1) KR102627084B1 (enExample)
CN (1) CN109310737B (enExample)
AU (1) AU2017274094B2 (enExample)
CA (1) CA3026140A1 (enExample)
DK (1) DK3463422T3 (enExample)
ES (1) ES2979305T3 (enExample)
WO (1) WO2017206898A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240058393A1 (en) * 2020-12-28 2024-02-22 Md Healthcare Inc. Composition comprising micrococcus luteus-derived extracellular vesicle for prevention or treatment of metabolic disease
KR102605753B1 (ko) * 2021-08-06 2023-11-29 주식회사 동운아나텍 인공지능 기반의 혈당 예측 시스템 및 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072524A1 (en) * 2012-11-12 2014-05-15 Ruprecht-Karls-Universität Heidelberg Lipopetides for use in treating liver diseases and cardiovascular diseases
WO2014105939A1 (en) * 2012-12-27 2014-07-03 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN104130316A (zh) * 2005-08-12 2014-11-05 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
CN102241744B (zh) * 2010-05-14 2015-03-04 上海贺普药业股份有限公司 一种病毒感染阻断剂、其药物组合物及其应用
EP3204030B1 (en) 2014-10-07 2022-04-27 Myr GmbH Combination therapy of hbv and hdv infection
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
EP3189850A1 (en) 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104130316A (zh) * 2005-08-12 2014-11-05 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
WO2014072524A1 (en) * 2012-11-12 2014-05-15 Ruprecht-Karls-Universität Heidelberg Lipopetides for use in treating liver diseases and cardiovascular diseases
WO2014105939A1 (en) * 2012-12-27 2014-07-03 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GenBank Accession No. EU554535.1, 08 April 2008 *

Also Published As

Publication number Publication date
CN109310737A (zh) 2019-02-05
EP3463422A1 (en) 2019-04-10
JP7684788B2 (ja) 2025-05-28
AU2017274094A1 (en) 2019-02-14
US11633454B2 (en) 2023-04-25
ES2979305T3 (es) 2024-09-25
JP2019520341A (ja) 2019-07-18
CA3026140A1 (en) 2017-12-07
EP3463422A4 (en) 2020-02-26
DK3463422T3 (da) 2024-07-22
KR20190015392A (ko) 2019-02-13
US20230414706A1 (en) 2023-12-28
CN109310737B (zh) 2023-05-05
US20200323951A1 (en) 2020-10-15
EP3463422B1 (en) 2024-05-22
KR102627084B1 (ko) 2024-01-19
WO2017206898A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
CN111225680B (zh) 非酒精性脂肪性肝病的治疗药物
CN106715466B (zh) 作为选择性胰高血糖素受体激动剂的毒蜥外泌肽-4衍生物
US20210196786A1 (en) Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors
CA2895755A1 (en) Functionalized exendin-4 derivatives
US20230414706A1 (en) Compositions and methods for treating metabolic diseases
AU2021229621B2 (en) Peptides as selective GIP receptor agonists
US20180050095A1 (en) Methods and compositions for treating hypoglycemic disorders
US20240360194A1 (en) New Peptides as Potent and Selective GIP Receptor Agonists
JP7672677B2 (ja) 全用量条件下でｂ型肝炎ウイルス関連肝疾患を治療する医薬品および方法
TW202506170A (zh) 糖尿病之治療
JP2025525365A (ja) 改良されたｇｌｐ－１受容体アゴニストを含む融合タンパク質およびその使用
HK1191551A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
WO2010121351A1 (en) Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)